Prosecution Insights
Last updated: October 01, 2026

Examiner: CANDELARIA, JULIANA IRENE

Tech Center 1600 • Art Units: 1600 1633 1634 1641 1674 1677

This examiner grants 0% of resolved cases

Analysis

Juliana Irene Candelaria is an examiner in Tech Center 1600 and Art Unit 1600. She has 3 resolved cases on record. Her allowance rate is 0.0 percent, meaning that none of her resolved cases resulted in an allowance. The median days to allowance for her cases is 1122, which is the time recorded for these resolutions. Her interview lift is 0.0 percent, indicating no change in outcome from interviews in these instances.

The 3 resolved cases are the basis for the 0.0 percent allowance rate and 0.0 percent interview lift. This very limited data set makes it difficult to establish a clear pattern for her examination style. Practitioners should note the 1600 tech center and 1600 art unit when approaching her cases. The 1122 days to allowance is the only available timeline metric. More cases are needed to establish a pattern beyond these 3 resolved cases. The 0.0 percent allowance rate reflects the current data available for her profile.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

0.0%
Allow Rate
-60.0% vs TC avg
31
Total Applications
+0.0%
Interview Lift
1122
Avg Prosecution Days
Based on 3 resolved cases, 2023–2026

Rejection Statute Breakdown

3.3%
§101 Eligibility
14.7%
§102 Novelty
42.7%
§103 Obviousness
26.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18344973 MATERIALS AND METHODS FOR BIOENGINEERED IPSC POPULATIONS Final Rejection JANSSEN BIOTECH, INC.
18733979 HYDROGEL, INKJET INK, METHOD FOR PRODUCING CELL CULTURE BODY, AND CELL-CONTAINING GEL PARTICLES AND METHOD FOR PRODUCING SAME Non-Final OA RICOH COMPANY, LTD.
18340917 NON-HUMAN ANIMALS HAVING A HUMANIZED CLEC9A GENE Final Rejection Regeneron Pharmaceuticals, Inc.
18115285 BIOREACTOR FOR ANTIBODY PRODUCTION Final Rejection Regeneron Pharmaceuticals, Inc.
18905388 METHODS AND MATERIALS FOR GALGT2 GENE THERAPY Non-Final OA RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
18854168 METHODS AND MATERIALS FOR TREATING SYNGAP1-ASSOCIATED NEURODEVELOPMENTAL DISORDERS Non-Final OA The Johns Hopkins University
15550951 MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES Final Rejection William Marsh Rice University
18717851 Method of Production of Organoids and Uses Thereof Non-Final OA Centre National de la Recherche Scientifique
18342930 LUNG CANCER MODELING USING NORMAL LUNG ORGANOID WITH LUNG CANCER CELLS Final Rejection THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
18425313 EXOSOME, PREPARATION METHOD THEREOF, USE THEREOF AND PHARMACEUTICAL COMPOSITION Non-Final OA China Medical University
17815469 EXOSOME ENRICHMENT BY ULTRAFILTRATION Non-Final OA NATIONAL YANG MING CHIAO TUNG UNIVERSITY
18352730 COMPOSITIONS AND METHODS FOR NEUROPROTECTION AND/OR NEUROREGENERATION Non-Final OA The Children's Medical Center Corporation

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month